DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate.
Read Disclaimer

Ionis Pharmaceuticals (Nasdaq: $IONS): TRYNGOLZA Wins FDA Approval in Severe Hypertriglyceridemia

IONS

The FDA approval of TRYNGOLZA in adults with severe hypertriglyceridemia turns olezarsen from a rare-disease FCS launch into a broader cardiometabolic commercial story. The key issue now is not simply whether the drug works, but how quickly Ionis can convert a stronger label, a larger addressable population and pancreatitis-risk messaging into real prescribing momentum.

HIVE Digital Technologies (Nasdaq/TSX: $HIVE): Bitcoin Mining, AI Infrastructure, Paraguay, Canada and the New Compute Trade

HIVE

HIVE is no longer just a public Bitcoin miner. The company is trying to become a dual-engine digital infrastructure platform, using renewable-powered mining scale, GPU infrastructure and BUZZ HPC to participate in the AI compute boom. The opportunity is real enough to monitor closely, but the equity remains exposed to Bitcoin volatility, dilution, capex intensity and major execution risk.

Definium Therapeutics (Nasdaq: $DFTX): DT120 Phase 3 Emerge Deep Dive After Positive MDD Data

DFTX

Definium has moved from a speculative late-stage psychedelic psychiatry story into a much more serious Phase 3 data story. The positive Emerge readout in major depressive disorder changes the market conversation around DT120 ODT, but it does not remove the key risks: replication, regulatory execution, controlled-substance scheduling, commercial infrastructure, reimbursement and future capital strategy.

$ADXN / $DFTX / $MLTX / $CVM — From the Biotech World Today: Four Smaller Headlines Worth Watching

Biotech Radar

Addex Therapeutics, Definium Therapeutics, MoonLake Immunotherapeutics and CEL-SCI do not belong to the same biotech story. But today’s updates show four very different types of biotech catalysts: a financial and pipeline update, a Phase 3 psychiatry readout event, long-term immunology data tied to a future BLA strategy, and an international commercialization pathway for an investigational oncology asset.

Keel Infrastructure Corp. (Nasdaq/TSX: $KEEL): From Bitcoin Miner To AI Power Infrastructure — A High-Beta Data Center Pivot To Watch

KEEL

Keel Infrastructure is trying to transform the former Bitfarms platform into a North American AI/HPC data center and power infrastructure story. The market narrative is powerful, the asset base is strategically relevant, and the balance sheet has been strengthened — but the investment case still depends on execution, customer leases, capital discipline and proof that megawatts can become durable infrastructure cash flow.

Biotech Catalyst Tape: Approval, Manufacturing Delay and the Next FDA Date — $SPRO / $ACHV / $VRDN

Biotech Tape

Three biotech catalyst stories are converging at the end of June: Spero/GSK have moved from binary FDA risk to Utebzi approval follow-through; Achieve Life Sciences has shifted from a clean PDUFA calendar story to a manufacturing-related resubmission path; and Viridian Therapeutics is approaching a June 30 FDA target action date for veligrotug in thyroid eye disease. The common thread is simple: in catalyst biotech, the calendar matters — but the label, manufacturing path, economics, launch readiness and balance sheet matter even more.

FedEx (NYSE: $FDX) Earnings Preview: The Real-Economy Checkpoint and the FedEx Freight Spin-Off Test — $FDX / $FDXF / $UPS

Fedex

FedEx reports Q4 FY26 on June 23, just weeks after completing the FedEx Freight spin-off and two days before FedEx Freight’s first separate Q4 call. That makes this more than an earnings preview. It is a test of the post-spin FedEx story, the “One FedEx” operating model, freight-cycle normalization, logistics demand, oil exposure, e-commerce activity, cost discipline, and the market’s willingness to reward transportation restructuring after a strong run.

The AI Infrastructure Rally Faces Its Next Reality Check: Micron Earnings And The Memory Bottleneck Trade — $MU / $NVDA / $AVGO

Micron

Micron Technology is about to report earnings at a moment when the market is treating artificial intelligence less like a single-stock story and more like a full infrastructure cycle. Nvidia still sits at the center of the trade. Broadcom has become one of the clearest public vehicles for custom AI accelerators and AI networking. But Micron occupies a different and increasingly important layer: the memory and storage layer that determines whether AI systems can feed accelerators, sustain inference workloads, handle longer context windows and scale data-center token output efficiently.

AI Power Bottleneck Trade: $SEI, $WTS and $BE Beyond the Chip Story

AI Power

The AI trade has spent most of the last cycle worshipping at the altar of GPUs, networking chips and hyperscale cloud capex. That made sense. Without compute, there is no AI boom. But the market is now being forced to confront a less glamorous and potentially more durable question: what happens when the servers are ready, the capital is available, the customer demand is real, but the power is not?

Lockheed Martin, Northrop Grumman and RTX ($LMT $NOC $RTX): Why the U.S. Air Force CCA Awards Mark a New Phase in Defense AI

Defense Ai

The U.S. Air Force has moved Collaborative Combat Aircraft from prototype momentum toward engineering, manufacturing development, production and software competition. General Atomics and Anduril won the airframe contracts, but Lockheed Martin, Northrop Grumman and RTX Collins Aerospace are now inside the mission autonomy software pool — making $LMT, $NOC and $RTX the public-market way to follow a defense-AI shift that could reshape airpower over the next decade.